Results 91 to 100 of about 77,174 (152)

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy. [PDF]

J Clin Invest
Moisoiu V, Lourman R, Szulzewsky F, Kessler T, Collotta G, Porro A, Bertolini A, Singer F, Cimino PJ, Hertler C, Wick W, Reifenberger G, Holland EC, Sartori AA, Weller M, Wirsching HG.   +15 more
europepmc   +1 more source

Radiological Response to Capecitabine and Temozolomide in an Elderly Patient with Metastatic Leiomyosarcoma: A Case Report. [PDF]

J Clin Med
Yalcin S, Kilinc C, Sahin TK, Dizdar O.
europepmc   +1 more source

Statement of Retraction: Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway. [PDF]

Bioengineered
europepmc   +1 more source

Estimating Permeabilities from Biased Molecular Dynamics with a Green-Kubo Formalism for Transport across the Blood-Brain Barrier. [PDF]

J Chem Inf Model
Jorgensen C.
europepmc   +1 more source

Ferroptosis-associated immune modulation enhances temozolomide efficacy in experimental glioblastoma: potential implications for T-cell infiltration and tumour microenvironment dynamics. [PDF]

Clin Exp Med
Rahaman S, Kushwaha R, Vohora D, Chakravarty S, Kamal A.   +4 more
europepmc   +1 more source

Sequential EGFR inhibition sensitizes glioblastoma to temozolomide. [PDF]

Trends Pharmacol Sci
Yu X, Wu R, Cheng SY.
europepmc   +1 more source

Optimizing the Stupp protocol for treatment of glioblastoma: eliminating age bias, enhancing treatment timing, use of stereotactically-guided sequential boost, and dexamethasone dosing. [PDF]

J Neurooncol
Sharpe MA, Baskin AM, Teh BS, Butler EB, Baskin DS.   +4 more
europepmc   +1 more source

Targeting Nectin-4 sensitizes glioblastoma to temozolomide. [PDF]

Front Pharmacol
Zhang XG, Wang H, Song JN.
europepmc   +1 more source

Differentiation therapy targeting indoleamine 2,3-dioxygenase 1 in glioblastoma cells <i>in vitro</i>. [PDF]

Mol Clin Oncol
Nishide K, Yamamuro S, Aida Y, Ozawa Y, Sano E, Yoshino A.   +5 more
europepmc   +1 more source

Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance.

J Clin Endocrinol Metab
Paes T, Feelders RA, Dogan F, Iyer AM, Kros JM, Schwarz Y, van Koetsveld PM, Hofland LJ.   +7 more
europepmc   +1 more source